Ident. | Authors (with country if any) | Title |
---|
000C54 (2018) |
Brian L. Venables [États-Unis] ; Ny Sin [États-Unis] ; Alan Xiangdong Wang [États-Unis] ; Li-Qiang Sun [États-Unis] ; Yong Tu [États-Unis] ; Dennis Hernandez [États-Unis] ; Amy Sheaffer [États-Unis] ; Min Lee [États-Unis] ; Cindy Dunaj [États-Unis] ; Guangzhi Zhai [États-Unis] ; Diana Barry [États-Unis] ; Jacques Friborg [États-Unis] ; Fei Yu [États-Unis] ; Jay Knipe [États-Unis] ; Jason Sandquist [États-Unis] ; Paul Falk [États-Unis] ; Dawn Parker [États-Unis] ; Andrew C. Good [États-Unis] ; Ramkumar Rajamani [États-Unis] ; Fiona Mcphee [États-Unis] ; Nicholas A. Meanwell [États-Unis] ; Paul M. Scola [États-Unis] | P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor. |
000E50 (2017) |
Li Wang [République populaire de Chine] ; Bo-Bo Bao [République populaire de Chine] ; Guo-Qing Song [République populaire de Chine] ; Cheng Chen [République populaire de Chine] ; Xu-Meng Zhang [République populaire de Chine] ; Wei Lu [République populaire de Chine] ; Zefang Wang [République populaire de Chine] ; Yan Cai [République populaire de Chine] ; Shuang Li [République populaire de Chine] ; Sheng Fu [République populaire de Chine] ; Fu-Hang Song [République populaire de Chine] ; Haitao Yang [République populaire de Chine] ; Jian-Guo Wang [République populaire de Chine] | Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study |
000F38 (2016) |
Fenghua Wang [République populaire de Chine] ; Cheng Chen [République populaire de Chine] ; Wenjie Tan [République populaire de Chine] ; Kailin Yang [États-Unis] ; Haitao Yang [République populaire de Chine] | Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design |
000F54 (2016) |
Haofeng Wang ; Song Xue ; Haitao Yang ; Cheng Chen | Recent progress in the discovery of inhibitors targeting coronavirus proteases |
001007 (2016) |
Vathan Kumar [Taïwan] ; Kian-Pin Tan [Taïwan] ; Ying-Ming Wang [Taïwan] ; Sheng-Wei Lin [Taïwan] ; Po-Huang Liang [Taïwan] | Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. |
001053 (2016) |
Hiroyuki Konno [Japon] ; Masaki Wakabayashi [Japon] ; Daiki Takanuma [Japon] ; Yota Saito [Japon] ; Kenichi Akaji [Japon] | Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease |
001056 (2016) |
Fenghua Wang [République populaire de Chine] ; Cheng Chen [République populaire de Chine] ; Xuemeng Liu [République populaire de Chine] ; Kailin Yang [États-Unis] ; Xiaoling Xu [République populaire de Chine] ; Haitao Yang [République populaire de Chine] | Crystal Structure of Feline Infectious Peritonitis Virus Main Protease in Complex with Synergetic Dual Inhibitors. |
001105 (2016) |
Kenta Teruya [Japon] ; Yasunao Hattori [Japon] ; Yasuhiro Shimamoto [Japon] ; Kazuya Kobayashi [Japon] ; Akira Sanjoh [Japon] ; Atsushi Nakagawa [Japon] ; Eiki Yamashita [Japon] ; Kenichi Akaji [Japon] | Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza‐decaline scaffold |
001297 (2015) |
Hyun Lee [États-Unis] ; Hao Lei [États-Unis] ; Bernard D. Santarsiero [États-Unis] ; Joseph L. Gatuz [États-Unis] ; Shuyi Cao [États-Unis] ; Amy J. Rice [États-Unis] ; Kavankumar Patel [États-Unis] ; Michael Z. Szypulinski [États-Unis] ; Isabel Ojeda ; Arun K. Ghosh [États-Unis] ; Michael E. Johnson [États-Unis] | Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. |
001541 (2014) |
Paul M. Scola [États-Unis] ; Li-Qiang Sun ; Alan Xiangdong Wang ; Jie Chen ; Ny Sin ; Brian L. Venables ; Sing-Yuen Sit ; Yan Chen ; Anthony Cocuzza ; Donna M. Bilder ; Stanley V. D'Andrea ; Barbara Zheng ; Piyasena Hewawasam ; Yong Tu ; Jacques Friborg ; Paul Falk ; Dennis Hernandez ; Steven Levine ; Chaoqun Chen ; Fei Yu ; Amy K. Sheaffer ; Guangzhi Zhai ; Diana Barry ; Jay O. Knipe ; Yong-Hae Han ; Richard Schartman ; Maria Donoso ; Kathy Mosure ; Michael W. Sinz ; Tatyana Zvyaga ; Andrew C. Good ; Ramkumar Rajamani ; Kevin Kish ; Jeffrey Tredup ; Herbert E. Klei ; Qi Gao ; Luciano Mueller ; Richard J. Colonno ; Dennis M. Grasela ; Stephen P. Adams ; James Loy ; Paul C. Levesque ; Huabin Sun ; Hong Shi ; Lucy Sun ; William Warner ; Danshi Li ; Jialong Zhu ; Nicholas A. Meanwell ; Fiona Mcphee | The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. |
001647 (2014) |
Yasuhiro Shimamoto [Japon] ; Yasunao Hattori [Japon] ; Kazuya Kobayashi [Japon] ; Kenta Teruya [Japon] ; Akira Sanjoh [Japon] ; Atsushi Nakagawa [Japon] ; Eiki Yamashita [Japon] ; Kenichi Akaji [Japon] | Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors |
001650 (2014) |
Rolf Hilgenfeld | From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design |
001834 (2013) |
Zhilin Ren [République populaire de Chine] ; Liming Yan ; Ning Zhang ; Yu Guo ; Cheng Yang ; Zhiyong Lou ; Zihe Rao | The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease. |
001847 (2013) |
Wei Liu [République populaire de Chine] ; He-Min Zhu [République populaire de Chine] ; Guo-Jun Niu [République populaire de Chine] ; En-Zhi Shi [République populaire de Chine] ; Jie Chen [République populaire de Chine] ; Bo Sun [République populaire de Chine] ; Wei-Qiang Chen [République populaire de Chine] ; Hong-Gang Zhou [République populaire de Chine] ; Cheng Yang [République populaire de Chine] | Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
001850 (2013) |
Hyun Lee [États-Unis] ; Shuyi Cao ; Kirk E. Hevener ; Lena Truong ; Joseph L. Gatuz ; Kavankumar Patel ; Arun K. Ghosh ; Michael E. Johnson | Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications. |
001876 (2013) |
Qi Zhao [États-Unis] ; Erin Weber ; Haitao Yang | Recent developments on coronavirus main protease/3C like protease inhibitors. |
001904 (2013) |
Sivakoteswara Rao Mandadapu [États-Unis] ; Pathum M. Weerawarna ; Allan M. Prior ; Roxanne Adeline Z. Uy ; Sridhar Aravapalli ; Kevin R. Alliston ; Gerald H. Lushington ; Yunjeong Kim ; Duy H. Hua ; Kyeong-Ok Chang ; William C. Groutas | Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus. |
001953 (2013) |
Jon Jacobs [États-Unis] ; Valerie Grum-Tokars ; Ya Zhou ; Mark Turlington ; S Adrian Saldanha ; Peter Chase ; Aimee Eggler ; Eric S. Dawson ; Yahira M. Baez-Santos ; Sakshi Tomar ; Anna M. Mielech ; Susan C. Baker ; Craig W. Lindsley ; Peter Hodder ; Andrew Mesecar ; Shaun R. Stauffer | Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. |
001961 (2013) |
Pillaiyar Thanigaimalai [Japon] ; Sho Konno ; Takehito Yamamoto ; Yuji Koiwai ; Akihiro Taguchi ; Kentaro Takayama ; Fumika Yakushiji ; Kenichi Akaji ; Shen-En Chen ; Aurash Naser-Tavakolian ; Arne Schön ; Ernesto Freire ; Yoshio Hayashi | Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies. |
001967 (2013) |
Sho Konno [Japon] ; Pillaiyar Thanigaimalai ; Takehito Yamamoto ; Kiyohiko Nakada ; Rie Kakiuchi ; Kentaro Takayama ; Yuri Yamazaki ; Fumika Yakushiji ; Kenichi Akaji ; Yoshiaki Kiso ; Yuko Kawasaki ; Shen-En Chen ; Ernesto Freire ; Yoshio Hayashi | Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety. |
001C75 (2012) |
Hyun Lee [États-Unis] ; Jaime Torres ; Lena Truong ; Rima Chaudhuri ; Anuradha Mittal ; Michael E. Johnson | Reducing agents affect inhibitory activities of compounds: results from multiple drug targets. |